These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

48 related articles for article (PubMed ID: 16879270)

  • 1. Laboratory performance measures: evidence against low-risk women explaining low detection rates of high-grade abnormalities. Updated cancer information.
    Mitchell HS
    Cytopathology; 2006 Aug; 17(4):210. PubMed ID: 16879270
    [No Abstract]   [Full Text] [Related]  

  • 2. Laboratory performance measures: evidence against low-risk women explaining low detection rates of high-grade abnormalities.
    Mitchell HS
    Cytopathology; 2005 Apr; 16(2):77-81. PubMed ID: 15787649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-grade cervical abnormalities and screening intervals in New South Wales, Australia.
    Schindeler S; Morrell S; Zuo Y; Baker D
    J Med Screen; 2008; 15(1):36-43. PubMed ID: 18416954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden.
    Andrae B; Kemetli L; Sparén P; Silfverdal L; Strander B; Ryd W; Dillner J; Törnberg S
    J Natl Cancer Inst; 2008 May; 100(9):622-9. PubMed ID: 18445828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The uptake of cervical cancer screening by renal transplant recipients.
    Courtney AE; Leonard N; O'Neill CJ; McNamee PT; Maxwell AP
    Nephrol Dial Transplant; 2009 Feb; 24(2):647-52. PubMed ID: 18952575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cervical cancer screening in medically underserved California Latina and non-Latina women: effect of age and regularity of Pap testing.
    Howell LP; Gurusinghe S; Tabnak F; Sciortino S
    Cancer Detect Prev; 2009; 32(5-6):372-9. PubMed ID: 19264426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of cervical cancer screening program at a rural community of South Africa.
    Hoque M; Hoque E; Kader SB
    East Afr J Public Health; 2008 Aug; 5(2):111-6. PubMed ID: 19024420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathways to diagnosis of cervical cancer: screening history, delay in follow up, and smear reading.
    Priest P; Sadler L; Peters J; Crengle S; Bethwaite P; Medley G; Jackson R
    BJOG; 2007 Apr; 114(4):398-407. PubMed ID: 17166215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cervical cancer screening among women in metropolitan areas of the United States by individual-level and area-based measures of socioeconomic status, 2000 to 2002.
    Coughlin SS; King J; Richards TB; Ekwueme DU
    Cancer Epidemiol Biomarkers Prev; 2006 Nov; 15(11):2154-9. PubMed ID: 17119040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The value of early cancer detection was confirmed for cervix cancer].
    Neumann G
    MMW Munch Med Wochenschr; 1979 Apr; 121(14):471. PubMed ID: 107431
    [No Abstract]   [Full Text] [Related]  

  • 11. Cervical cancer screening in Thailand: an overview.
    Sriamporn S; Khuhaprema T; Parkin M
    J Med Screen; 2006; 13 Suppl 1():S39-43. PubMed ID: 17227641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Routine audit of large-scale cervical cancer screening programs.
    Cuzick J
    J Natl Cancer Inst; 2008 May; 100(9):605-6. PubMed ID: 18445817
    [No Abstract]   [Full Text] [Related]  

  • 13. [Cervical cancer screening: restoration or reconstruction?].
    Riethmuller D
    Gynecol Obstet Fertil; 2009; 37(7-8):671-9. PubMed ID: 19577501
    [No Abstract]   [Full Text] [Related]  

  • 14. Rapid pre-screening of cervical smears as a method of internal quality control in a cervical screening programme.
    Tavares SB; de Sousa NL; Manrique EJ; de Albuquerque ZB; Zeferino LC; Amaral RG
    Cytopathology; 2008 Aug; 19(4):254-9. PubMed ID: 18476988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjunctive high-risk human papillomavirus DNA testing is a useful option for disease risk assessment in patients with negative Papanicolaou tests without an endocervical/transformation zone sample.
    Zhao C; Austin RM
    Cancer; 2008 Aug; 114(4):242-8. PubMed ID: 18484643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Are analyses of cytological cervix smears from young women more harmful than beneficial?].
    Skjeldestad FE; Hagen B; Hagmar B; Iversen OE; Juvkam KH; Steen R; Thoresen S; Hareide B
    Tidsskr Nor Laegeforen; 2007 Jun; 127(13):1782-5. PubMed ID: 17599128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of invasive cervical cancer in relation to management of abnormal Pap smear results.
    Silfverdal L; Kemetli L; Andrae B; Sparén P; Ryd W; Dillner J; Strander B; Törnberg S
    Am J Obstet Gynecol; 2009 Aug; 201(2):188.e1-7. PubMed ID: 19560117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inadequacy of cervical cancer screening among urban recent immigrants: a population-based study of physician and laboratory claims in Toronto, Canada.
    Lofters A; Glazier RH; Agha MM; Creatore MI; Moineddin R
    Prev Med; 2007 Jun; 44(6):536-42. PubMed ID: 17467782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Addressing Taiwan's high incidence of cervical cancer: factors associated with the Nation's low compliance with Papanicolaou screening in Taiwan.
    Liao CC; Wang HY; Lin RS; Hsieh CY; Sung FC
    Public Health; 2006 Dec; 120(12):1170-6. PubMed ID: 17074376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overview of the cytology laboratory: specimen processing through diagnosis.
    Joste N
    Obstet Gynecol Clin North Am; 2008 Dec; 35(4):549-63; viii. PubMed ID: 19061816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.